History
  • No items yet
midpage
Thomas Mckay v. Novartis Pharmaceutical Cor
751 F.3d 694
5th Cir.
2014
Read the full case

Background

  • McKay v. Novartis court proceedings spanned MDL transfer to TN and remand to Texas, involving Aredia and Zometa and allegations of osteonecrosis of the jaw.
  • MDL court applied Texas choice-of-law and § 82.007(a) presumption against liability for failure-to-warn claims, granting partial summary judgment for Novartis.
  • Remand court in Texas granted summary judgment on remaining claims, treating all failure-to-warn claims as precluded by § 82.007(a) and severing other issues.
  • McKays moved for Rule 56(d) discovery to contest Texas law applicability; the court found information was available and denied relief.
  • On appeal, McKays challenge Rule 56(d) ruling, remand-law-of-the-case treatment, off-label rebuttal arguments, and warranty-notice compliance.
  • Texas breach-of-warranty claims were dismissed for failure to provide statutorily required notice under Tex. Bus. & Com. Code § 2.607.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Did the MDL court abuse Rule 56(d) discretion? McKay asserts discovery delay justified relief. Novartis contends information was available and discovery dilatory. No abuse; discovery was not diligently pursued.
Did remand court correctly apply law of the case to § 82.007 and its rebuttals? Lofton-based rebuttals and off-label evidence should evade the presumption. MDL ruling on § 82.007(a) controls; law of the case forecloses new arguments. Remand court did not err in applying law of the case.
Are McKays' warranty claims barred for lack of statutorily required notice? Notice was satisfied via Dr. Leibowitz and related proceedings. Notification to a remote manufacturer was insufficient; notice must be to Novartis. Yes; warranty claims barred for lack of proper notice; remand court properly granted summary judgment.
Did Texas choice-of-law determine the governing substantive law for the failure-to-warn claims? California connections may show California law applies. Texas ties dominate; Texas law governs substantive questions. Texas law applies; McKays' evidence not overwhelming to disturb prior ruling.

Key Cases Cited

  • Lofton v. McNeil Consumer & Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012) (Lofton preempts part of § 82.007(b)(1) otherwise; supports limitations on rebuttal.)
  • In re Ford Motor Co., 591 F.3d 406 (5th Cir. 2009) (Law of the case framework for transferee decisions in MDL.)
  • Xerox Corp. v. Genmoora Corp., 888 F.2d 345 (5th Cir. 1989) (Law-of-the-case principle; relitigation avoided in MDL context.)
  • Beattie v. Madison Cnty. Sch. Dist., 254 F.3d 595 (5th Cir. 2001) (Rule 56(d) relief requires diligent pursuit of discovery.)
  • Guillory on Behalf of Guillory v. United States, 699 F.2d 781 (5th Cir. 1983) (Weight given to state law factors in choice-of-law analysis.)
Read the full case

Case Details

Case Name: Thomas Mckay v. Novartis Pharmaceutical Cor
Court Name: Court of Appeals for the Fifth Circuit
Date Published: May 27, 2014
Citation: 751 F.3d 694
Docket Number: 13-50404
Court Abbreviation: 5th Cir.